Compare YEXT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YEXT | PRTA |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.4M | 449.7M |
| IPO Year | 2017 | 2013 |
| Metric | YEXT | PRTA |
|---|---|---|
| Price | $6.76 | $9.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $7.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 689.5K | 397.2K |
| Earning Date | 06-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.82 | N/A |
| EPS | 0.02 | ★ 0.26 |
| Revenue | ★ $170,201,000.00 | $814,000.00 |
| Revenue This Year | $3.95 | $1,111.38 |
| Revenue Next Year | $2.46 | N/A |
| P/E Ratio | $325.00 | ★ $35.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.27 | $7.73 |
| 52 Week High | $9.20 | $11.80 |
| Indicator | YEXT | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 72.95 | 50.55 |
| Support Level | $4.77 | $8.83 |
| Resistance Level | $8.04 | $9.36 |
| Average True Range (ATR) | 0.21 | 0.37 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 92.83 | 39.53 |
Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.